ดูเหมือนว่ามีข้อผิดพลาดเกิดขึ้นขณะกำลังโหลดหน้าเพจนี้.
ทีมงานของเราได้รับแจ้งแล้วแต่กรุณาติดต่อเราด้วยการใช้ วิจิทบริการสนับสนุนทางอีเมล หากปัญหายังคงมีอยู่
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | 53.0x - 58.6x | 55.8x |
| Selected Fwd EBITDA Multiple | 42.9x - 47.5x | 45.2x |
| Fair Value | ₩2,001 - ₩2,179 | ₩2,090 |
| Upside | -25.0% - -18.4% | -21.7% |
| Benchmarks | Ticker | Full Ticker |
| Avenir Wellness Solutions, Inc. | AVRW | OTCPK:AVRW |
| Komipharm International Co., Ltd. | A041960 | KOSDAQ:A041960 |
| Aprogen Biologics Inc. | A003060 | KOSE:A003060 |
| Korean Drug Co., Ltd. | A014570 | KOSDAQ:A014570 |
| ChoA Pharmaceutical Co., LTD. | A034940 | KOSDAQ:A034940 |
| CMG Pharmaceutical Co., Ltd. | A058820 | KOSDAQ:A058820 |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| AVRW | A041960 | A003060 | A014570 | A034940 | A058820 | ||
| OTCPK:AVRW | KOSDAQ:A041960 | KOSE:A003060 | KOSDAQ:A014570 | KOSDAQ:A034940 | KOSDAQ:A058820 | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | 6.1% | NM- | -1.5% | |
| 3Y CAGR | NM- | NM- | NM- | -21.4% | NM- | NM- | |
| Latest Twelve Months | 57.3% | 438.7% | 19.9% | -27.1% | -16.1% | -22.0% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | -423.1% | -0.1% | -19.2% | 15.4% | -3.5% | 5.6% | |
| Prior Fiscal Year | -141.0% | -6.4% | -56.4% | 10.4% | -10.2% | 6.0% | |
| Latest Fiscal Year | -136.6% | 15.8% | -58.6% | 8.5% | -11.9% | 4.4% | |
| Latest Twelve Months | -145.7% | 15.8% | -58.6% | 8.5% | -11.9% | 4.4% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 4.66x | 6.77x | 3.61x | 0.46x | 0.74x | 3.24x | |
| EV / LTM EBITDA | -3.2x | 42.8x | -6.2x | 5.4x | -6.2x | 73.4x | |
| EV / LTM EBIT | -3.1x | 64.2x | -4.2x | 8.2x | -4.7x | 314.2x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | -6.2x | -3.2x | 42.8x | ||||
| Historical EV / LTM EBITDA | 39.2x | 56.3x | 73.4x | ||||
| Selected EV / LTM EBITDA | 53.0x | 55.8x | 58.6x | ||||
| (x) LTM EBITDA | 4,366 | 4,366 | 4,366 | ||||
| (=) Implied Enterprise Value | 231,570 | 243,758 | 255,945 | ||||
| (-) Non-shareholder Claims * | 43,292 | 43,292 | 43,292 | ||||
| (=) Equity Value | 274,861 | 287,049 | 299,237 | ||||
| (/) Shares Outstanding | 138.9 | 138.9 | 138.9 | ||||
| Implied Value Range | 1,978.95 | 2,066.71 | 2,154.46 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 1,978.95 | 2,066.71 | 2,154.46 | 2,670.00 | |||
| Upside / (Downside) | -25.9% | -22.6% | -19.3% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | AVRW | A041960 | A003060 | A014570 | A034940 | A058820 | |
| Enterprise Value | 9 | 397,226 | 242,842 | 33,128 | 45,826 | 327,551 | |
| (+) Cash & Short Term Investments | 0 | 22,448 | 38,319 | 19,000 | 5,447 | 76,794 | |
| (+) Investments & Other | 0 | 1,010 | 91,994 | 331 | 3,068 | 46,463 | |
| (-) Debt | (9) | (43,839) | (154,017) | (81) | (24,689) | (79,965) | |
| (-) Other Liabilities | 0 | (3,257) | (199) | 0 | 2,815 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 1 | 373,587 | 218,938 | 52,378 | 32,467 | 370,842 | |
| (/) Shares Outstanding | 78.9 | 69.7 | 311.0 | 10.9 | 31.0 | 138.9 | |
| Implied Stock Price | 0.01 | 5,360.00 | 704.00 | 4,800.00 | 1,048.00 | 2,670.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.01 | 5,360.00 | 704.00 | 4,800.00 | 1,048.00 | 2,670.00 | |
| Trading Currency | USD | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |